Pulmonary Embolism and COVID-19 (COVID-19-PE)

May 1, 2021 updated by: Uşak University

Evaluation of the Patients With COVID-19 in Terms of Pulmonary Embolism

The charts of patients who developed pulmonary embolism in the course of COVID-19 will be evaluated, retrospectively. Clinical features and laboratory data will be analyzed.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Patients with COVID-19 infection will be evaluated retrospectively. Demographic data, clinical and laboratory findings will be recorded. Findings of patients with pulmonary embolism and withour pulmonary embolism will be compared.

Study Type

Observational

Enrollment (Anticipated)

600

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Turkey
      • Usak, Turkey, 64200
        • Recruiting
        • Uşak University
        • Contact:
        • Sub-Investigator:
          • Canan Akkus, M.D.
        • Sub-Investigator:
          • Hakan Yilmaz, M.D.
        • Sub-Investigator:
          • Barış Sevinç, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

All COVID-19 patients with positive RT-PCR tests will be analyzed retrospectively. Patients with and without pulmonary embolism will be compared in terms of age, gender, side disease, hospitalization in intensive care, mortality rates etc.

Description

Inclusion Criteria:

- All patients with positive RT-PCR for COVID-19

Exclusion Criteria:

- All patients with negative RT-PCR for COVID-19

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Covid-19 Patients with Pulmonary embolism
Clinically demonstared cases infected with COVID-19 who developed pulmonary embolism.
Other: intensive care unit admission ratio
intensive care unit admission ratio
Covid-19 Patients without Pulmonary embolism
Clinically demonstared cases infected with COVID-19 who did not develop pulmonary embolism.
Other: intensive care unit admission ratio
intensive care unit admission ratio

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
pulmonary embolism
Time Frame: 1 year
development of pulmonary embolism
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intensive care unit
Time Frame: 1 year
need for admission to intensive care unit
1 year
mortality
Time Frame: 1 year
mortality rate due to pulmonary embolism
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Uşak University

Investigators

  • Principal Investigator: Cevdet Duran, M.D., Uşak University Medical School

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2020

Primary Completion (Anticipated)

June 1, 2021

Study Completion (Anticipated)

December 1, 2021

Study Registration Dates

First Submitted

October 14, 2020

First Submitted That Met QC Criteria

October 15, 2020

First Posted (Actual)

October 19, 2020

Study Record Updates

Last Update Posted (Actual)

May 4, 2021

Last Update Submitted That Met QC Criteria

May 1, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UU-PE001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Covid-19

Clinical Trials on intensive care unit admission ratio

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe